Janssen Cilag Ltd

Lobbying Organisation Janssen Cilag Ltd

Date published 21 Sep, 2016

Relevant Matter Matters involving public funds

Public Policy Area Health

Period 1 May, 2016 to 31 Aug, 2016

Specific Details The reimbursement of an innovative medicine

Intended results To seek an update on the timeline for reimbursement for Imbruvica, an innovative targeted therapy for rare blood cancers.

Name of person primarily responsible for lobbying on this activity Conor Sweeney

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

An e-mail to Senator Burke and Senator Buttimer requesting a meeting.

Meeting (2-5)

A meeting with Senator Burke and a meeting with Senator Buttimer requesting that they seek an update regarding the reimbursement timelines for Imbruvica from the HSE and Minister Harris.

Letter (1)

Letter to Minister Harris asking him to review the application of Ibrutinib and seeking an update on the reimbursement timeline of Imbruvica

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Colm Burke Senator (Seanad)

Simon Harris Minister (Department of Health)

Jerry Buttimer Senator (Seanad)